4-Aminohippuric Acid
The serum concentration of Pazopanib can be increased when it is combined with Aminohippuric acid.
Abemaciclib
The serum concentration of Pazopanib can be increased when it is combined with Abemaciclib.
Abiraterone
The serum concentration of Pazopanib can be increased when it is combined with Abiraterone.
Advertisement
Acetaminophen
The serum concentration of Pazopanib can be increased when it is combined with Acetaminophen.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Pazopanib.
Afatinib
The serum concentration of Pazopanib can be increased when it is combined with Afatinib.
Advertisement
Albendazole
The serum concentration of Pazopanib can be increased when it is combined with Albendazole.
Albuterol
Salbutamol may increase the QTc-prolonging activities of Pazopanib.
Alectinib
The serum concentration of Pazopanib can be increased when it is combined with Alectinib.
Advertisement
Alfentanil
The serum concentration of Pazopanib can be increased when it is combined with Alfentanil.
Alfuzosin
Alfuzosin may increase the QTc-prolonging activities of Pazopanib.
Aluminum
The serum concentration of Pazopanib can be decreased when it is combined with Aluminium.
Aluminum Hydroxide
The serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The serum concentration of Pazopanib can be decreased when it is combined with Almasilate.
Amantadine
The serum concentration of Pazopanib can be increased when it is combined with Amantadine.
Amiodarone
The serum concentration of Pazopanib can be increased when it is combined with Amiodarone.
Amitriptyline
The serum concentration of Pazopanib can be increased when it is combined with Amitriptyline.
Amlodipine
The serum concentration of Pazopanib can be increased when it is combined with Amlodipine.
Amoxapine
Amoxapine may increase the QTc-prolonging activities of Pazopanib.
Amprenavir
The serum concentration of Pazopanib can be increased when it is combined with Amprenavir.
Amsacrine
The serum concentration of Pazopanib can be increased when it is combined with Amsacrine.
Anagrelide
Pazopanib may increase the QTc-prolonging activities of Anagrelide.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Pazopanib.
Anhydrous Tacrolimus
The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Pazopanib is combined with Anthrax immune globulin human.
Apalutamide
The serum concentration of Pazopanib can be decreased when it is combined with Apalutamide.
Apomorphine
Apomorphine may increase the QTc-prolonging activities of Pazopanib.
Aprepitant
The serum concentration of Pazopanib can be increased when it is combined with Aprepitant.
Arformoterol
Arformoterol may increase the QTc-prolonging activities of Pazopanib.
Aripiprazole
Aripiprazole may increase the QTc-prolonging activities of Pazopanib.
Arsenic Trioxide
Pazopanib may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Pazopanib may increase the QTc-prolonging activities of Artemether.
Asenapine
Asenapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Astemizole
The serum concentration of Pazopanib can be increased when it is combined with Astemizole.
Atazanavir
The serum concentration of Pazopanib can be increased when it is combined with Atazanavir.
Atenolol
The serum concentration of Pazopanib can be increased when it is combined with Atenolol.
Atomoxetine
The metabolism of Pazopanib can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Pazopanib is combined with Atorvastatin.
Azelastine
The serum concentration of Pazopanib can be increased when it is combined with Azelastine.
Azithromycin
The serum concentration of Pazopanib can be increased when it is combined with Azithromycin.
Baricitinib
The serum concentration of Pazopanib can be increased when it is combined with Baricitinib.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pazopanib.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Pazopanib is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Pazopanib is combined with Bacillus calmette-guerin substrain tice live antigen.
Bedaquiline
Pazopanib may increase the QTc-prolonging activities of Bedaquiline.
Benzocaine
The serum concentration of Pazopanib can be increased when it is combined with Benzocaine.
Bepridil
The serum concentration of Pazopanib can be increased when it is combined with Bepridil.
Betaxolol
The metabolism of Pazopanib can be decreased when combined with Betaxolol.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Pazopanib.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Pazopanib.
Biperiden
The serum concentration of Pazopanib can be increased when it is combined with Biperiden.
Bismuth Subcitrate
The serum concentration of Pazopanib can be decreased when it is combined with Bismuth Subcitrate.
Boceprevir
The serum concentration of Pazopanib can be increased when it is combined with Boceprevir.
Bortezomib
The metabolism of Pazopanib can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Pazopanib can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Pazopanib can be increased when it is combined with Bosutinib.
Bosutinib monohydrate
The serum concentration of Pazopanib can be increased when it is combined with Bosutinib.
Brigatinib
The serum concentration of Pazopanib can be increased when it is combined with Brigatinib.
Bromocriptine
The serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.
Buprenorphine
The serum concentration of Pazopanib can be increased when it is combined with Buprenorphine.
Bupropion
The metabolism of Pazopanib can be decreased when combined with Bupropion.
Buserelin
Buserelin may increase the QTc-prolonging activities of Pazopanib.
Buspirone
The serum concentration of Pazopanib can be increased when it is combined with Buspirone.
Cabazitaxel
The serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Pazopanib.
Caffeine
The serum concentration of Pazopanib can be increased when it is combined with Caffeine.
Calcium Carbonate
The serum concentration of Pazopanib can be decreased when it is combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The serum concentration of Pazopanib can be decreased when it is combined with Calcium Carbonate.
Canagliflozin
The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.
Canagliflozin Anhydrous
The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.
Candesartan
The serum concentration of Pazopanib can be increased when it is combined with Candesartan.
Candesartan Cilexetil
The serum concentration of Pazopanib can be increased when it is combined with Candesartan cilexetil.
Cannabidiol
The serum concentration of Pazopanib can be increased when it is combined with Cannabidiol.
Captopril
The serum concentration of Pazopanib can be increased when it is combined with Captopril.
Carbamazepine
The serum concentration of Pazopanib can be increased when it is combined with Carbamazepine.
Carvedilol
The serum concentration of Pazopanib can be increased when it is combined with Carvedilol.
Caspofungin
The serum concentration of Pazopanib can be increased when it is combined with Caspofungin.
Celecoxib
The metabolism of Pazopanib can be decreased when combined with Celecoxib.
Ceritinib
The serum concentration of Pazopanib can be increased when it is combined with Ceritinib.
Cerivastatin
Cerivastatin may increase the hepatotoxic activities of Pazopanib.
Chloroquine
The serum concentration of Pazopanib can be increased when it is combined with Chloroquine.
Chlorpromazine
The serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.
Chlorpropamide
The serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.
Chlorprothixene
The serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.
Cholecalciferol
The metabolism of Pazopanib can be decreased when combined with Cholecalciferol.
Cholesterol
The serum concentration of Pazopanib can be increased when it is combined with Cholesterol.
Cilazapril
The serum concentration of Pazopanib can be increased when it is combined with Cilazapril.
Cimetidine
The serum concentration of Pazopanib can be increased when it is combined with Cimetidine.
Cinacalcet
The metabolism of Pazopanib can be decreased when combined with Cinacalcet.
Ciprofloxacin
The serum concentration of Pazopanib can be increased when it is combined with Ciprofloxacin.
Cisapride
Pazopanib may increase the QTc-prolonging activities of Cisapride.
Citalopram
The serum concentration of Pazopanib can be increased when it is combined with Citalopram.
Clarithromycin
The serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.
Clemastine
The metabolism of Pazopanib can be decreased when combined with Clemastine.
Clobazam
The metabolism of Pazopanib can be decreased when combined with Clobazam.
Clofazimine
The serum concentration of Pazopanib can be increased when it is combined with Clofazimine.
Clofezone
The serum concentration of Pazopanib can be decreased when it is combined with Rabeprazole.
Clomipramine
The serum concentration of Pazopanib can be increased when it is combined with Clomipramine.
Clotrimazole
The serum concentration of Pazopanib can be increased when it is combined with Clotrimazole.
Clozapine
Clozapine may increase the QTc-prolonging activities of Pazopanib.
Cobicistat
The serum concentration of Pazopanib can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Pazopanib can be decreased when combined with Cocaine.
Colchicine
The serum concentration of Pazopanib can be increased when it is combined with Colchicine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Pazopanib.
Crisaborole
The metabolism of Pazopanib can be decreased when combined with Crisaborole.
Crizotinib
The serum concentration of Pazopanib can be increased when it is combined with Crizotinib.
Cyclophosphamide
The serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.
Cyclosporine
The serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.
Cyproterone Acetate
The serum concentration of Pazopanib can be decreased when it is combined with Cyproterone acetate.
Dabrafenib
The serum concentration of Pazopanib can be decreased when it is combined with Dabrafenib.
Daclatasvir
The serum concentration of Pazopanib can be increased when it is combined with Daclatasvir.
Dactinomycin
The serum concentration of Pazopanib can be increased when it is combined with Dactinomycin.
Darifenacin
The metabolism of Pazopanib can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Pazopanib can be increased when it is combined with Darunavir.
Dasabuvir
The serum concentration of Pazopanib can be increased when it is combined with Dasabuvir.
Dasatinib
The serum concentration of Pazopanib can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Pazopanib can be increased when it is combined with Dasatinib.
Daunorubicin
The serum concentration of Pazopanib can be increased when it is combined with Daunorubicin.
Deferasirox
The serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.
Degarelix
Degarelix may increase the QTc-prolonging activities of Pazopanib.
Delavirdine
The metabolism of Pazopanib can be decreased when combined with Delavirdine.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Pazopanib.
Desflurane
Desflurane may increase the QTc-prolonging activities of Pazopanib.
Desipramine
The serum concentration of Pazopanib can be increased when it is combined with Desipramine.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Pazopanib.
Desloratadine
The serum concentration of Pazopanib can be increased when it is combined with Desloratadine.
Dexamethasone
The serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.
Dexlansoprazole
The serum concentration of Pazopanib can be decreased when it is combined with Dexlansoprazole.
Dextromethorphan
The serum concentration of Pazopanib can be increased when it is combined with Dextromethorphan.
Diclofenac
The serum concentration of Pazopanib can be increased when it is combined with Diclofenac.
Diethylstilbestrol
The serum concentration of Pazopanib can be increased when it is combined with Diethylstilbestrol.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Pazopanib.
Digoxin
The serum concentration of Pazopanib can be increased when it is combined with Digoxin.
Dihydroergotamine
The serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine.
Diltiazem
The serum concentration of Pazopanib can be increased when it is combined with Diltiazem.
Diphenhydramine
The metabolism of Pazopanib can be decreased when combined with Diphenhydramine.
Dipyridamole
The serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.
Disopyramide
Pazopanib may increase the QTc-prolonging activities of Disopyramide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.
Dofetilide
Pazopanib may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Dolasetron may increase the QTc-prolonging activities of Pazopanib.
Domperidone
Pazopanib may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The metabolism of Pazopanib can be decreased when combined with Dosulepin.
Doxazosin
The serum concentration of Pazopanib can be increased when it is combined with Doxazosin.
Doxepin
The serum concentration of Pazopanib can be increased when it is combined with Doxepin.
Doxorubicin
The serum concentration of Pazopanib can be increased when it is combined with Doxorubicin.
Doxorubicin Hydrochloride
The serum concentration of Pazopanib can be increased when it is combined with Doxorubicin.
Doxycycline
The metabolism of Pazopanib can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Pazopanib can be decreased when combined with Doxycycline.
Dronedarone
The serum concentration of Pazopanib can be increased when it is combined with Dronedarone.
Droperidol
Droperidol may increase the QTc-prolonging activities of Pazopanib.
Duloxetine
The metabolism of Pazopanib can be decreased when combined with Duloxetine.
Efavirenz
The metabolism of Pazopanib can be decreased when combined with Efavirenz.
Eliglustat
Pazopanib may increase the QTc-prolonging activities of Eliglustat.
Eltrombopag
The serum concentration of Pazopanib can be increased when it is combined with Eltrombopag.
Enalapril
The serum concentration of Pazopanib can be increased when it is combined with Enalapril.
Enasidenib
The serum concentration of Pazopanib can be increased when it is combined with Enasidenib.
Enzalutamide
The serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.
Epinastine
Epinastine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ergonovine
The serum concentration of Pazopanib can be increased when it is combined with Ergonovine.
Ergotamine
The serum concentration of Pazopanib can be increased when it is combined with Ergotamine.
Eribulin
Eribulin may increase the QTc-prolonging activities of Pazopanib.
Erlotinib
The serum concentration of Pazopanib can be increased when it is combined with Erlotinib.
Erythromycin
The serum concentration of Pazopanib can be increased when it is combined with Erythromycin.
Escitalopram
Pazopanib may increase the QTc-prolonging activities of Escitalopram.
Esomeprazole
The serum concentration of Pazopanib can be decreased when it is combined with Esomeprazole.
Estradiol
The serum concentration of Pazopanib can be increased when it is combined with Estradiol.
Estradiol 3-Benzoate
The serum concentration of Pazopanib can be increased when it is combined with Estradiol benzoate.
Estradiol acetate
The serum concentration of Pazopanib can be increased when it is combined with Estradiol acetate.
Estradiol Cypionate
The serum concentration of Pazopanib can be increased when it is combined with Estradiol cypionate.
Estradiol Valerate
The serum concentration of Pazopanib can be increased when it is combined with Estradiol valerate.
Estramustine
The serum concentration of Pazopanib can be increased when it is combined with Estramustine.
Estrone
The serum concentration of Pazopanib can be increased when it is combined with Estrone.
Etoposide
The serum concentration of Pazopanib can be increased when it is combined with Etoposide.
Etravirine
The serum concentration of Pazopanib can be increased when it is combined with Etravirine.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Pazopanib.
Famotidine
Famotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Felbamate
Felbamate may increase the QTc-prolonging activities of Pazopanib.
Felodipine
The serum concentration of Pazopanib can be increased when it is combined with Felodipine.
Fentanyl
The serum concentration of Pazopanib can be increased when it is combined with Fentanyl.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pazopanib.
Fexofenadine
The serum concentration of Pazopanib can be increased when it is combined with Fexofenadine.
Fidaxomicin
The serum concentration of Pazopanib can be increased when it is combined with Fidaxomicin.
Fingolimod
Pazopanib may increase the immunosuppressive activities of Fingolimod.
Flecainide
Flecainide may increase the QTc-prolonging activities of Pazopanib.
Fluconazole
The serum concentration of Pazopanib can be increased when it is combined with Fluconazole.
Fluoxetine
The serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.
Flupenthixol
The serum concentration of Pazopanib can be increased when it is combined with Flupentixol.
Fluphenazine
The serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.
Flurazepam
The serum concentration of Pazopanib can be increased when it is combined with Flurazepam.
Fluvastatin
Fluvastatin may increase the hepatotoxic activities of Pazopanib.
Fluvoxamine
The serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine.
Formoterol
Formoterol may increase the QTc-prolonging activities of Pazopanib.
Fosamprenavir
The metabolism of Pazopanib can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Pazopanib can be increased when it is combined with Fosaprepitant.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Pazopanib.
Fosphenytoin
The serum concentration of Pazopanib can be decreased when it is combined with Fosphenytoin.
Fusidate
The serum concentration of Pazopanib can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Pazopanib can be increased when it is combined with Fusidic Acid.
Gadobenate
Gadobenic acid may increase the QTc-prolonging activities of Pazopanib.
Galantamine
Galantamine may increase the QTc-prolonging activities of Pazopanib.
Gefitinib
The serum concentration of Pazopanib can be increased when it is combined with Gefitinib.
Gemifloxacin
Gemifloxacin may increase the QTc-prolonging activities of Pazopanib.
Gemifloxacin Mesylate
Gemifloxacin may increase the QTc-prolonging activities of Pazopanib.
Genistein
The serum concentration of Pazopanib can be increased when it is combined with Genistein.
Glecaprevir
The serum concentration of Pazopanib can be increased when it is combined with Glecaprevir.
Glyburide
The serum concentration of Pazopanib can be increased when it is combined with Glyburide.
Glycerin
The serum concentration of Pazopanib can be increased when it is combined with Glycerin.
Goserelin
Goserelin may increase the QTc-prolonging activities of Pazopanib.
Gramicidin
The serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.
Granisetron
Granisetron may increase the QTc-prolonging activities of Pazopanib.
Grepafloxacin
The serum concentration of Pazopanib can be increased when it is combined with Grepafloxacin.
Haloperidol
The serum concentration of Pazopanib can be increased when it is combined with Haloperidol.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Pazopanib is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Pazopanib is combined with Hepatitis B Vaccine (Recombinant).
Hesperetin
The serum concentration of Pazopanib can be increased when it is combined with Hesperetin.
Histrelin
Histrelin may increase the QTc-prolonging activities of Pazopanib.
Hydrocortisone
The serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone.
Hydrotalcite
The serum concentration of Pazopanib can be decreased when it is combined with Hydrotalcite.
Hydroxyzine
Hydroxyzine may increase the QTc-prolonging activities of Pazopanib.
Hypoxis hemerocallidea root extract
The serum concentration of Pazopanib can be decreased when it is combined with St. John's Wort.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Pazopanib.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Pazopanib.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Pazopanib.
Ibutilide
Pazopanib may increase the QTc-prolonging activities of Ibutilide.
Idelalisib
The serum concentration of Pazopanib can be increased when it is combined with Idelalisib.
Iloperidone
Pazopanib may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The serum concentration of Pazopanib can be increased when it is combined with Imatinib.
Imipramine
The serum concentration of Pazopanib can be increased when it is combined with Imipramine.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Pazopanib.
Indapamide
Indapamide may increase the QTc-prolonging activities of Pazopanib.
Indinavir
The serum concentration of Pazopanib can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Pazopanib can be increased when it is combined with Indinavir.
Indomethacin
The serum concentration of Pazopanib can be increased when it is combined with Indomethacin.
Irbesartan
The metabolism of Pazopanib can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Pazopanib can be increased when it is combined with Isavuconazole.
Isavuconazonium
The serum concentration of Pazopanib can be increased when it is combined with Isavuconazonium.
Isoflurane
Isoflurane may increase the QTc-prolonging activities of Pazopanib.
Isoniazid
The metabolism of Pazopanib can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Pazopanib can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Pazopanib can be increased when it is combined with Itraconazole.
Ivabradine
Ivabradine may increase the QTc-prolonging activities of Pazopanib.
Ivacaftor
The serum concentration of Pazopanib can be increased when it is combined with Ivacaftor.
Ivermectin
The serum concentration of Pazopanib can be increased when it is combined with Ivermectin.
Ketamine
The serum concentration of Pazopanib can be increased when it is combined with Ketamine.
Ketoconazole
The serum concentration of Pazopanib can be increased when it is combined with Ketoconazole.
Lansoprazole
The serum concentration of Pazopanib can be increased when it is combined with Lansoprazole.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Pazopanib.
Leflunomide
The risk or severity of adverse effects can be increased when Pazopanib is combined with Leflunomide.
Lenvatinib
Pazopanib may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Pazopanib may increase the QTc-prolonging activities of Lenvatinib.
Letermovir
The serum concentration of Pazopanib can be increased when it is combined with Letermovir.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Pazopanib.
Levofloxacin
The serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.
Levofloxacin Anhydrous
The serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.
Lidocaine
The serum concentration of Pazopanib can be increased when it is combined with Lidocaine.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Pazopanib.
Lithium
Lithium may increase the QTc-prolonging activities of Pazopanib.
Lithium Cation
Lithium may increase the QTc-prolonging activities of Pazopanib.
Lomitapide
The serum concentration of Pazopanib can be increased when it is combined with Lomitapide.
Loperamide
The serum concentration of Pazopanib can be increased when it is combined with Loperamide.
Lopinavir
The serum concentration of Pazopanib can be increased when it is combined with Lopinavir.
Loratadine
The serum concentration of Pazopanib can be increased when it is combined with Loratadine.
Lorcaserin
The metabolism of Pazopanib can be decreased when combined with Lorcaserin.
Losartan
The serum concentration of Pazopanib can be increased when it is combined with Losartan.
Lovastatin
The serum concentration of Pazopanib can be increased when it is combined with Lovastatin.
Luliconazole
The serum concentration of Pazopanib can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Pazopanib can be increased when it is combined with Lumacaftor.
Lumefantrine
Pazopanib may increase the QTc-prolonging activities of Lumefantrine.
Magaldrate
The serum concentration of Pazopanib can be decreased when it is combined with Magaldrate.
Magnesium Hydroxide
The serum concentration of Pazopanib can be decreased when it is combined with Magnesium hydroxide.
Magnesium Oxide
The serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.
Magnesium Trisilicate
The serum concentration of Pazopanib can be decreased when it is combined with Magnesium Trisilicate.
Manidipine
The metabolism of Pazopanib can be decreased when combined with Manidipine.
Maprotiline
The serum concentration of Pazopanib can be increased when it is combined with Maprotiline.
Mebendazole
The serum concentration of Pazopanib can be increased when it is combined with Mebendazole.
Mefloquine
The serum concentration of Pazopanib can be increased when it is combined with Mefloquine.
Megestrol Acetate
The serum concentration of Pazopanib can be increased when it is combined with Megestrol acetate.
Meprobamate
The serum concentration of Pazopanib can be increased when it is combined with Meprobamate.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Pazopanib.
Methadone
The serum concentration of Pazopanib can be increased when it is combined with Methadone.
Methantheline
Methantheline can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methotrimeprazine
The metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Pazopanib.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Pazopanib.
Metoclopramide
Metoclopramide may increase the QTc-prolonging activities of Pazopanib.
Metoprolol
The serum concentration of Pazopanib can be increased when it is combined with Metoprolol.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Pazopanib.
Mexiletine
The metabolism of Pazopanib can be decreased when combined with Mexiletine.
Mibefradil
The serum concentration of Pazopanib can be increased when it is combined with Mibefradil.
Miconazole
The serum concentration of Pazopanib can be increased when it is combined with Miconazole.
Midazolam
The serum concentration of Pazopanib can be increased when it is combined with Midazolam.
Midostaurin
The metabolism of Pazopanib can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Pazopanib can be increased when it is combined with Mifepristone.
Mirabegron
The metabolism of Pazopanib can be decreased when combined with Mirabegron.
Mirtazapine
Mirtazapine may increase the QTc-prolonging activities of Pazopanib.
Mitomycin
The serum concentration of Pazopanib can be increased when it is combined with Mitomycin.
Mitotane
The serum concentration of Pazopanib can be decreased when it is combined with Mitotane.
Mitoxantrone
The serum concentration of Pazopanib can be increased when it is combined with Mitoxantrone.
Moexipril
Moexipril may increase the QTc-prolonging activities of Pazopanib.
Morphine
The serum concentration of Pazopanib can be increased when it is combined with Morphine.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Pazopanib.
Naltrexone
The serum concentration of Pazopanib can be increased when it is combined with Naltrexone.
Naringenin
The serum concentration of Pazopanib can be increased when it is combined with Naringenin.
Natalizumab
The risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.
Nefazodone
The serum concentration of Pazopanib can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Pazopanib can be increased when it is combined with Nelfinavir.
Neostigmine
The serum concentration of Pazopanib can be increased when it is combined with Neostigmine.
Netupitant
The serum concentration of Pazopanib can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Pazopanib can be decreased when it is combined with Nevirapine.
Nicardipine
The serum concentration of Pazopanib can be increased when it is combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Pazopanib.
Nifedipine
The serum concentration of Pazopanib can be increased when it is combined with Nifedipine.
Nilotinib
The serum concentration of Pazopanib can be increased when it is combined with Nilotinib.
Nisoldipine
The serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.
Nitrazepam
The serum concentration of Pazopanib can be increased when it is combined with Nitrazepam.
Nitrendipine
The serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.
Nizatidine
Nizatidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Pazopanib.
Nortriptyline
Nortriptyline may increase the QTc-prolonging activities of Pazopanib.
Novobiocin
The serum concentration of Pazopanib can be increased when it is combined with Novobiocin.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Pazopanib.
Octreotide
Octreotide may increase the QTc-prolonging activities of Pazopanib.
Ofloxacin
Ofloxacin may increase the QTc-prolonging activities of Pazopanib.
Olanzapine
Olanzapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Olaparib
The metabolism of Pazopanib can be decreased when combined with Olaparib.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Pazopanib.
Omeprazole
The serum concentration of Pazopanib can be increased when it is combined with Omeprazole.
Ondansetron
Ondansetron may increase the QTc-prolonging activities of Pazopanib.
Osimertinib
The serum concentration of Pazopanib can be increased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Pazopanib.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pazopanib.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Pazopanib.
p-Aminohippurate
The serum concentration of Pazopanib can be increased when it is combined with Aminohippuric acid.
Paclitaxel
The serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.
Palbociclib
The serum concentration of Pazopanib can be increased when it is combined with Palbociclib.
Paliperidone
Pazopanib may increase the QTc-prolonging activities of Paliperidone.
Palmitate
The serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.
Palmitic Acid
The serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.
Panobinostat
The serum concentration of Pazopanib can be increased when it is combined with Panobinostat.
Pantoprazole
The serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.
Paregoric
The serum concentration of Pazopanib can be increased when it is combined with Morphine.
Paroxetine
The serum concentration of Pazopanib can be increased when it is combined with Paroxetine.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Pazopanib.
Peginterferon Alfa-2b
The serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
Pentamidine may increase the QTc-prolonging activities of Pazopanib.
Pentobarbital
The serum concentration of Pazopanib can be decreased when it is combined with Pentobarbital.
Perflutren
Perflutren may increase the QTc-prolonging activities of Pazopanib.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Pazopanib.
Perindopril
The serum concentration of Pazopanib can be increased when it is combined with Perindopril.
Phenobarbital
The serum concentration of Pazopanib can be decreased when it is combined with Phenobarbital.
Phenytoin
The serum concentration of Pazopanib can be decreased when it is combined with Phenytoin.
Pibrentasvir
The serum concentration of Pazopanib can be increased when it is combined with Pibrentasvir.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.
Pimozide
The serum concentration of Pazopanib can be increased when it is combined with Pimozide.
Pioglitazone
The metabolism of Pazopanib can be decreased when combined with Pioglitazone.
Pitavastatin
Pitavastatin may increase the hepatotoxic activities of Pazopanib.
Ponatinib
The serum concentration of Pazopanib can be increased when it is combined with Ponatinib.
Posaconazole
The serum concentration of Pazopanib can be increased when it is combined with Posaconazole.
Pravastatin
The serum concentration of Pazopanib can be increased when it is combined with Pravastatin.
Prazosin
The serum concentration of Pazopanib can be increased when it is combined with Prazosin.
Prednisone
The serum concentration of Pazopanib can be increased when it is combined with Prednisone.
Primaquine
Primaquine may increase the QTc-prolonging activities of Pazopanib.
Primidone
The serum concentration of Pazopanib can be decreased when it is combined with Primidone.
Probenecid
The serum concentration of Pazopanib can be increased when it is combined with Probenecid.
Procainamide
Pazopanib may increase the QTc-prolonging activities of Procainamide.
Progesterone
The serum concentration of Pazopanib can be increased when it is combined with Progesterone.
Promazine
Promazine may increase the QTc-prolonging activities of Pazopanib.
Promethazine
The serum concentration of Pazopanib can be increased when it is combined with Promethazine.
Propafenone
The serum concentration of Pazopanib can be increased when it is combined with Propafenone.
Propofol
Propofol may increase the QTc-prolonging activities of Pazopanib.
Propranolol
The serum concentration of Pazopanib can be increased when it is combined with Propranolol.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Pazopanib.
Protriptyline
The serum concentration of Pazopanib can be increased when it is combined with Protriptyline.
Quercetin
The serum concentration of Pazopanib can be increased when it is combined with Quercetin.
Quetiapine
Pazopanib may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Pazopanib may increase the QTc-prolonging activities of Quetiapine.
Quinacrine
The serum concentration of Pazopanib can be increased when it is combined with Quinacrine.
Quinidine
The serum concentration of Pazopanib can be increased when it is combined with Quinidine.
Quinine
The serum concentration of Pazopanib can be increased when it is combined with Quinine.
Rabeprazole
The serum concentration of Pazopanib can be decreased when it is combined with Rabeprazole.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Pazopanib is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Pazopanib is combined with Rabies virus inactivated antigen, A.
Ranitidine
The serum concentration of Pazopanib can be increased when it is combined with Ranitidine.
Ranolazine
The serum concentration of Pazopanib can be increased when it is combined with Ranolazine.
Reboxetine
The serum concentration of Pazopanib can be increased when it is combined with Reboxetine.
Regorafenib
The serum concentration of Pazopanib can be increased when it is combined with Regorafenib.
Reserpine
The serum concentration of Pazopanib can be increased when it is combined with Reserpine.
Rifabutin
The serum concentration of Pazopanib can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Pazopanib can be increased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Pazopanib can be decreased when it is combined with Rifapentine.
Rilpivirine
The serum concentration of Pazopanib can be increased when it is combined with Rilpivirine.
Risperidone
Risperidone may increase the QTc-prolonging activities of Pazopanib.
Ritonavir
The serum concentration of Pazopanib can be increased when it is combined with Ritonavir.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Pazopanib.
Rolapitant
The serum concentration of Pazopanib can be increased when it is combined with Rolapitant.
Ropinirole
The metabolism of Pazopanib can be decreased when combined with Ropinirole.
Rosiglitazone
The metabolism of Pazopanib can be decreased when combined with Rosiglitazone.
Rosuvastatin
Rosuvastatin may increase the hepatotoxic activities of Pazopanib.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Pazopanib is combined with Rotavirus Vaccine.
Roxatidine Acetate
Roxatidine acetate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Pazopanib is combined with Rubella virus vaccine.
Rucaparib
The serum concentration of Pazopanib can be increased when it is combined with Rucaparib.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Pazopanib.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Pazopanib is combined with Salmonella typhi ty21a live antigen.
Saquinavir
The serum concentration of Pazopanib can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Pazopanib can be increased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Pazopanib can be decreased when used in combination with Sarilumab.
Scopolamine
The serum concentration of Pazopanib can be increased when it is combined with Scopolamine.
Scopolamine Hydrobromide
The serum concentration of Pazopanib can be increased when it is combined with Scopolamine.
Secobarbital
The metabolism of Pazopanib can be increased when combined with Secobarbital.
Selegiline
The serum concentration of Pazopanib can be increased when it is combined with Selegiline.
Sertraline
The serum concentration of Pazopanib can be increased when it is combined with Sertraline.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Pazopanib.
Sildenafil
The metabolism of Pazopanib can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Pazopanib can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Pazopanib can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Pazopanib can be increased when it is combined with Simvastatin.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pazopanib.
Sirolimus
The serum concentration of Pazopanib can be increased when it is combined with Sirolimus.
Sodium Bicarbonate
The serum concentration of Pazopanib can be decreased when it is combined with Sodium bicarbonate.
Solifenacin
Solifenacin may increase the QTc-prolonging activities of Pazopanib.
Sorafenib
The serum concentration of Pazopanib can be increased when it is combined with Sorafenib.
Sotalol
Pazopanib may increase the QTc-prolonging activities of Sotalol.
Spironolactone
The serum concentration of Pazopanib can be increased when it is combined with Spironolactone.
ST. JOHN'S WORT EXTRACT
The serum concentration of Pazopanib can be decreased when it is combined with St. John's Wort.
Sulfamethoxazole
The metabolism of Pazopanib can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.
Sulfinpyrazone
The serum concentration of Pazopanib can be increased when it is combined with Sulfinpyrazone.
Sulfisoxazole
Sulfisoxazole may increase the QTc-prolonging activities of Pazopanib.
Sumatriptan
The serum concentration of Pazopanib can be increased when it is combined with Sumatriptan.
Sumatriptan Succinate
The serum concentration of Pazopanib can be increased when it is combined with Sumatriptan.
Sunitinib
The serum concentration of Pazopanib can be increased when it is combined with Sunitinib.
Tacrine
The serum concentration of Pazopanib can be increased when it is combined with Tacrine.
Tacrolimus
The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.
Tamoxifen
The serum concentration of Pazopanib can be increased when it is combined with Tamoxifen.
Telaprevir
The serum concentration of Pazopanib can be increased when it is combined with Telaprevir.
Telavancin
Telavancin may increase the QTc-prolonging activities of Pazopanib.
Telithromycin
The serum concentration of Pazopanib can be increased when it is combined with Telithromycin.
Telmisartan
The serum concentration of Pazopanib can be increased when it is combined with Telmisartan.
Temsirolimus
The serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.
Tenofovir Disoproxil
The metabolism of Pazopanib can be decreased when combined with Tenofovir disoproxil.
Terazosin
The serum concentration of Pazopanib can be increased when it is combined with Terazosin.
Terbinafine
The metabolism of Pazopanib can be decreased when combined with Terbinafine.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Pazopanib.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Pazopanib.
Terfenadine
The serum concentration of Pazopanib can be increased when it is combined with Terfenadine.
Teriflunomide
The serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.
Testosterone
The serum concentration of Pazopanib can be increased when it is combined with Testosterone.
Testosterone Cypionate
The serum concentration of Pazopanib can be increased when it is combined with Testosterone cypionate.
Testosterone Enanthate
The serum concentration of Pazopanib can be increased when it is combined with Testosterone enanthate.
Testosterone Undecanoate
The serum concentration of Pazopanib can be increased when it is combined with Testosterone undecanoate.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Pazopanib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tetrabenazine
Pazopanib may increase the QTc-prolonging activities of Tetrabenazine.
Tetrahydrocannabinol
The serum concentration of Pazopanib can be increased when it is combined with Dronabinol.
Theophylline
The metabolism of Pazopanib can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Pazopanib can be decreased when combined with Theophylline.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Pazopanib.
Thiothixene
Thiothixene may increase the QTc-prolonging activities of Pazopanib.
Ticagrelor
The serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.
Ticlopidine
The metabolism of Pazopanib can be decreased when combined with Ticlopidine.
Tipranavir
The metabolism of Pazopanib can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Pazopanib.
Tocilizumab
The serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.
Tofacitinib
Pazopanib may increase the immunosuppressive activities of Tofacitinib.
Tolterodine
Tolterodine may increase the QTc-prolonging activities of Pazopanib.
Tolvaptan
The serum concentration of Pazopanib can be increased when it is combined with Tolvaptan.
Topotecan
The serum concentration of Pazopanib can be increased when it is combined with Topotecan.
Toremifene
Pazopanib may increase the QTc-prolonging activities of Toremifene.
Tranylcypromine
The metabolism of Pazopanib can be decreased when combined with Tranylcypromine.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Pazopanib.
Trazodone
Trazodone may increase the QTc-prolonging activities of Pazopanib.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Pazopanib.
Trifluoperazine
The serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.
Triflupromazine
The serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.
Trimethoprim
The serum concentration of Pazopanib can be increased when it is combined with Trimethoprim.
Trimipramine
The serum concentration of Pazopanib can be increased when it is combined with Trimipramine.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Pazopanib.
Troleandomycin
The serum concentration of Pazopanib can be increased when it is combined with Troleandomycin.
Tromethamine
The serum concentration of Pazopanib can be decreased when it is combined with Tromethamine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Pazopanib is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Pazopanib is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Vandetanib
The serum concentration of Pazopanib can be increased when it is combined with Vandetanib.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Pazopanib.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Pazopanib is combined with Varicella Zoster Vaccine (Live/Attenuated).
Velpatasvir
The serum concentration of Pazopanib can be increased when it is combined with Velpatasvir.
Vemurafenib
The serum concentration of Pazopanib can be increased when it is combined with Vemurafenib.
Venlafaxine
The serum concentration of Pazopanib can be increased when it is combined with Venlafaxine.
Verapamil
The serum concentration of Pazopanib can be increased when it is combined with Verapamil.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Pazopanib.
Vinblastine
The serum concentration of Pazopanib can be increased when it is combined with Vinblastine.
Vincristine
The serum concentration of Pazopanib can be increased when it is combined with Vincristine.
Vinorelbine
The serum concentration of Pazopanib can be increased when it is combined with Vinorelbine.
Vismodegib
The serum concentration of Pazopanib can be increased when it is combined with Vismodegib.
Voriconazole
The serum concentration of Pazopanib can be increased when it is combined with Voriconazole.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Pazopanib.
Voxilaprevir
The serum concentration of Pazopanib can be increased when it is combined with Voxilaprevir.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Pazopanib is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Pazopanib is combined with Yellow Fever Vaccine.
Ziprasidone
Pazopanib may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Pazopanib may increase the QTc-prolonging activities of Zuclopenthixol.
